Keith Quincy Tanis

Keith Quincy Tanis

Auto-generated profile, based on publicly available information

Keith Quincy Tanis

Molecular Profiling Department, Merck Research Laboratories, West Point, PA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Neuron
Verified
Journal Article
Closed access
ABAmy Bernard
Amy Bernard
LLLaura S. Lubbers
Laura S. Lubbers
KTKeith Q. Tanis
Keith Q. Tanis
RLRui Luo
Rui Luo
APAlexei A. Podtelezhnikov
Alexei A. Podtelezhnikov
ELEd S. Lein
Ed S. Lein

1 June 2003 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
KTKeith Q. Tanis
Keith Q. Tanis
DVDarren R. Veach
Darren R. Veach
HDHenry S. Duewel
Henry S. Duewel
WBWilliam G. Bornmann
William G. Bornmann
AKAnthony Koleske
Anthony Koleske
The activities of the related Abl and Arg nonreceptor tyrosine kinases are kept under tight control in cells, but exposure to several different stimuli results in a two- to fivefold stimulation of kinase activity. Following the breakdown of inhibitory intramolecular interactions, Abl activation requires phosphorylation on several tyrosine residues, including a tyrosine in its activation loop. These activating phosphorylations have been proposed to occur either through autophosphorylation by Abl in trans or through phosphorylation of Abl by the Src nonreceptor tyrosine kinase. We show here that these two pathways mediate phosphorylation at distinct sites in Abl and Arg and have additive effects on Abl and Arg kinase activation. Abl and Arg autophosphorylate at several sites outside the activation loop, leading to 5.2- and 6.2-fold increases in kinase activity, respectively. We also find that the Src family kinase Hck phosphorylates the Abl and Arg activation loops, leading to an additional twofold stimulation of kinase activity. The autoactivation pathway may allow Abl family kinases to integrate or amplify cues relayed by Src family kinases from cell surface receptors.

31 May 2018 in Fluids and Barriers of the CNS
Verified
Journal Article
Open access
PDF file
ESEdward G. Stopa
Edward G. Stopa
KTKeith Q. Tanis
Keith Q. Tanis
MMMiles C. Miller
Miles C. Miller
ENElena V. Nikonova
Elena V. Nikonova
APAlexei A. Podtelezhnikov
Alexei A. Podtelezhnikov
CJConrad E. Johanson
Conrad E. Johanson
In Alzheimer’s disease, there are striking changes in CSF composition that relate to altered choroid plexus (CP) function. Studying CP tissue gene expression at the blood–cerebrospinal fluid barrier could provide further insight into the epithelial and stromal responses to neurodegenerative disease states. Transcriptome-wide Affymetrix microarrays were used to determine disease-related changes in gene expression in human CP. RNA from post-mortem samples of the entire lateral ventricular choroid plexus was extracted from 6 healthy controls (Ctrl), 7 patients with advanced (Braak and Braak stage III–VI) Alzheimer’s disease (AD), 4 with frontotemporal dementia (FTD) and 3 with Huntington’s disease (HuD). Statistics and agglomerative clustering were accomplished with MathWorks, MatLab; and gene set annotations by comparing input sets to GeneGo ( http://www.genego.com ) and Ingenuity ( http://www.ingenuity.com ) pathway sets. Bonferroni-corrected hypergeometric p-values of < 0.1 were considered a significant overlap between sets. Pronounced differences in gene expression occurred in CP of advanced AD patients vs. Ctrls. Metabolic and immune-related pathways including acute phase response, cytokine, cell adhesion, interferons, and JAK-STAT as well as mTOR were significantly enriched among the genes upregulated. Methionine degradation, claudin-5 and protein translation genes were downregulated. Many gene expression changes in AD patients were observed in FTD and HuD (e.g., claudin-5, tight junction downregulation), but there were significant differences between the disease groups. In AD and HuD (but not FTD), several neuroimmune-modulating interferons were significantly enriched (e.g., in AD: IFI-TM1, IFN-AR1, IFN-AR2, and IFN-GR2). AD-associated expression changes, but not those in HuD and FTD, were enriched for upregulation of VEGF signaling and immune response proteins, e.g., interleukins. HuD and FTD patients distinctively displayed upregulated cadherin-mediated adhesion. Our transcript data for human CP tissue provides genomic and mechanistic insight for differential expression in AD vs. FTD vs. HuD for stromal as well as epithelial components. These choroidal transcriptome characterizations elucidate immune activation, tissue functional resiliency, and CSF metabolic homeostasis. The BCSFB undergoes harmful, but also important functional and adaptive changes in neurodegenerative diseases; accordingly, the enriched JAK-STAT and mTOR pathways, respectively, likely help the CP in adaptive transcription and epithelial repair and/or replacement when harmed by neurodegeneration pathophysiology. We anticipate that these precise CP translational data will facilitate pharmacologic/transgenic therapies to alleviate dementia.

1 October 2014 in SLEEP
Verified
Journal Article
Closed access
Erna Sif ArnardóttirErna Sif Arnardóttir
Erna Sif Arnardóttir
ENElena V. Nikonova
Elena V. Nikonova
KSKeith R. Shockley
Keith R. Shockley
APAlexei A. Podtelezhnikov
Alexei A. Podtelezhnikov
RARon C. Anafi
Ron C. Anafi
APAllan I. Pack
Allan I. Pack
S and full research articles published in SLEEP, the official journal of the APSS. Sleep and sleep disorder scientific findings.

1 January 2010 in Neuropharmacology
Verified
Journal Article
Closed access
CWChristopher J. Winrow
Christopher J. Winrow
KTKeith Q. Tanis
Keith Q. Tanis
DRDuane R. Reiss
Duane R. Reiss
Alison RigbyAlison Rigby
Alison Rigby
JUJason M. Uslaner
Jason M. Uslaner
JRJohn J. Renger
John J. Renger

28 December 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
APAlexei A. Podtelezhnikov
Alexei A. Podtelezhnikov
KTKeith Q. Tanis
Keith Q. Tanis
MNMichael Nebozhyn
Michael Nebozhyn
WRWilliam J. Ray
William J. Ray
DSDavid J. Stone
David J. Stone
ALAndrey P. Loboda
Andrey P. Loboda
Alzheimer's disease (AD) is a complex neurodegenerative disorder that diverges from the process of normal brain aging by unknown mechanisms. We analyzed the global structure of age- and disease-dependent gene expression patterns in three regions from more than 600 brains. Gene expression variation could be almost completely explained by four transcriptional biomarkers that we named BioAge (biological age), Alz (Alzheimer), Inflame (inflammation), and NdStress (neurodegenerative stress). BioAge captures the first principal component of variation and includes genes statistically associated with neuronal loss, glial activation, and lipid metabolism. Normally BioAge increases with chronological age, but in AD it is prematurely expressed as if some of the subjects were 140 years old. A component of BioAge, Lipa, contains the AD risk factor APOE and reflects an apparent early disturbance in lipid metabolism. The rate of biological aging in AD patients, which cannot be explained by BioAge, is associated instead with NdStress, which includes genes related to protein folding and metabolism. Inflame, comprised of inflammatory cytokines and microglial genes, is broadly activated and appears early in the disease process. In contrast, the disease-specific biomarker Alz was selectively present only in the affected areas of the AD brain, appears later in pathogenesis, and is enriched in genes associated with the signaling and cell adhesion changes during the epithelial to mesenchymal (EMT) transition. Together these biomarkers provide detailed description of the aging process and its contribution to Alzheimer's disease progression.